Aventis/VaxGen AIDS Vaccine Phase III Update Will Be Heard By Advisory Committee Sept. 23
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Vaccines & Related Biologics Advisory Committee will discuss ongoing study of Aventis' ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX. The committee will review Aventis' meningococcal conjugate vaccine Menactra Sept. 22.
You may also be interested in...
Sanofi-Aventis' Menactra Demonstrates Noninferiority To Menomune, FDA Says
The meningococcal vaccine Menactra met its primary safety endpoint of noninferiority in severe systemic adverse events. Sanofi-Aventis failed to show lot consistency within predefined equivalence limits, FDA says.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).